Aardvark pauses two obesity drug trials as it reviews side effects

Reuters03-24
Aardvark pauses two obesity drug trials as it reviews side effects

March 23 (Reuters) - Aardvark Therapeutics AARD.O said on Monday it has voluntarily paused two mid-stage studies testing its experimental combination treatment for obesity as it reviews side effects associated with one of the drugs.

  • The combination treatment, ARD-201, was being tested to induce weight loss and prevent weight regain among patients who have lost about 15% of body weight on the popular GLP-1 class of drugs, which includes Eli Lilly's LLY.N Zepbound and Novo Nordisk's NOVOb.CO Wegovy.

  • ARD-201 is a combination of Aardvark's experimental drug, ARD-101, and Merck's diabetes drug MRK.N Januvia, chemically known as sitagliptin.

  • ARD-101 is designed to trigger the release of multiple gut-peptide hormones, including GLP-1, to regulate hunger.

  • Last month, the company identified heart-related side effects during safety monitoring of ARD-101 in a healthy-volunteer study. It then paused a late-stage trial testing ARD-101 in patients with a rare genetic disorder called Prader-Willi syndrome.

  • Aardvark said it expects to provide further updates on the drugs in the second quarter of 2026.

(Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)

((Mariam.ESunny@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment